Tarsus Pharmaceuticals’ Strategic Partnership with LianBio

Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP advised Tarsus Pharmaceuticals, Inc. on the deal.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company, and LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets, announced a strategic partnership to develop and commercialize TP-03 in Greater China (mainland China, Hong Kong, Taiwan, and Macau). TP-03 is a first-in-class investigational therapeutic in development for the treatment of Demodex blepharitis and Meibomian Gland Disease (MGD), eye conditions with significant unmet treatment needs.

As part of this strategic partnership, LianBio will obtain exclusive rights to develop and commercialize TP-03 in Greater China, and Tarsus will receive a $15 million upfront payment. Tarsus may also receive up to $185 million in development and commercialization milestones, including $10 million by June 30, 2021, and $45 million over the next 12 months for anticipated near term clinical milestones. 

The Gunderson deal team was led by Brendan McCarthy (Picture) and included Shu Hu.

 

Involved fees earner: Shu Hu – Gunderson Dettmer; Brendan McCarthy – Gunderson Dettmer;

Law Firms: Gunderson Dettmer;

Clients: Tarsus Pharmaceuticals, Inc.;

Author: Martina Bellini